



THURSDAY 5 SEPTEMBER 2019

08:30	<p>Teaching Course 1 - The hypothalamus 08:30-10:00 08:30-08:50 - Introduction on role in the maintenance of homeostasis (P. Holland, UK) 08:50-09:10 - Role in attack initiation (L. Schulte Germany) 09:10-09:30 - Role in initiation of premonitory symptoms (F.H. Maniyar, UK) 09:30-09:50 - Sensory input and role in mediating migraine symptoms in response to pain, light, sound, and smell (R. Nosedá US) 09:50-10:00 - Discussion</p>	<p>Teaching Course 2 - The neurobiology of medication overuse headache and its relation to addiction 08:30-10:00 Chair: R. Jensen (Denmark)  08:30-08:55 - Medication Overuse and Chronic Migraine – to withdraw or not withdraw? (J. Pijpers, The Netherlands) 08:55-09:20 - Is MOH a form of addiction? (E. Leroux, Canada) 09:20-09:45 - Why do opioids induce MOH in migraine patients (but not in chronic pain patients) and why they worsen somatic/musculoskeletal pain in low back pain patients, but not in migraine patients? (J.Rau, USA) 09:45-10:00 - Discussion</p>	<p>Teaching Course 3 - Migraine comorbidities and the challenges they add to diagnosis and management 08:30-10:00 Chair: S.Evers (Germany)  08:30-08:45 - Vascular (CVD, brain lesions and stroke, hypertension, PFD, diabetes) (MiJi Lee, Korea) 08:45-09:00 - Psychiatric (depression, bipolar, anxiety, panic, suicide ideation) (SP. Park, Korea) 09:00-09:15 - Epilepsy: Clinical challenges in diagnosis Epilepsy (F. Dach, Brazil) 09:15-09:30 - Chronic and Musculoskeletal pain (chronic low back pain, neck pain, fibromyalgia) (S-J. Wang, Taiwan) 09:30-09:45 - Sleep and BMI (sleep dysfunction, insomnia and narcolepsy, restless legs) (A. Sinclair, UK) 09:45-10:00 - Discussion</p>	<p>Teaching Course 7 - Primary Considerations for Clinicians 08:30-10:00 Moderator: Allan Purdy 08:30-08:35 - Introduction and Overview of Course (A. Purdy, Canada) 08:35-09:00 - Essential Diagnostic Knowledge (A. Purdy, Canada) 09:00-09:25 - Migraine and Friends - Essentials (B. Jenkins, Australia) 09:25-09:50 - Tackling the TACs and Neuralgias (A. Cohen, UK) 09:50-10:00 - Audience participation</p>
10:00	<p>Break 10:00 - 10:30</p>			
10:30	<p>Teaching Course 4 - Animal models of headache and the value they add to headache medicine 10:30-12:00 10:30-10:45 - Animal model of migraine aura (SP. Chen, Taiwan) 10:45-11:00 - Animal model of chronic migraine and medication overuse headache (A.A. Pradhan, USA) 11:00-11:15 - Animal model of post-traumatic headache (D. Levy, USA) 11:15-11:30 - Animal model of post-ictal headache (A. Melo-Carrillo, USA) 11:30-11:45 - Orofacial pain (Z Helyes, Hungary) 11:45-12:00 - Discussion</p>	<p>Teaching Course 5 - Biomarkers of migraine in body fluids 10:30-12:00 Chair: E. Loder (USA)  10:30-10:50 How to measure biomarkers of disease in body fluid (M. Giera, The Netherlands) 10:50-11:10 - Vascular biomarkers of migraine (G. Tietjen USA) 11:10-11:30 - Migraine biomarkers in the CSF (R. Van Dongen, The Netherlands) 11:30-11:50 - Biomarker of chronic migraine (J. Pascual, Spain) 11:50-12:00 - Discussion</p>	<p>Teaching Course 6 - Research for early career scientists and clinicians 10:30-12:00 Chair: S- J. Wang (Taiwan)  10:30-10:50 - Defining a successful path for a clinician in headache research (J. Olesen, Denmark) 10:50-11:10 - Defining a successful path for a basic scientist in headache research (D. Krause, USA) 11:10-11:30 - The principles of successful path for publications (Cephalalgia, A. May, Germany) 11:30-11:50 - Understanding the review process (Headache, T. Ward, USA) 11:50-12:00 - Discussion</p>	<p>Teaching Course 7 - Secondary Considerations for clinicians 10:30-12:00 Moderator: Allan Purdy 10:30-10:50 - Sorting out the Secondaries (M. Levin, USA) 10:50 -11:10 - Principles of Treatment (M. Peres, Brazil) 11:10-11:30 - Case Based Sessions with Faculty #1 (P. Pozo-Rosich, Spain) 11:30-11:50 - Case Based Sessions with Faculty #2 (S. Evers, Germany) 11:50-12:00 - And in the End! Putting it all together</p>
12:00	<p>Break - Lunch bags for TC attendees 12:00 - 12:30</p>			
12:30	<p>Opening Ceremony and Presidential Symposium Novel Ways in Migraine Therapy 12:30-15:00 (1) D. Hay, New Zealand, (2) KA Haanes, Denmark, (3) DN Krause, CA, USA.</p>			
15:00	<p>IHC Special Lecture 15:00 - 16:00 Chair: R. Burstein (USA) R. Jensen, Denmark</p>			
16:00	<p>Coffee break, poster and exhibition viewing 16:00 - 16:20</p>			<p>Exhibition Open 16:00 - 19:30</p>
16:20	<p>World Brain Day for Migraine and Other Headaches 16:20 - 17:00 16:20-16:22 - Introduction (L. Edvinsson, Sweden) 16:22 - 16:30 - Global Headache and Migraine Advocacy (D. Dodick, USA) 16:30-16:45 - Migraine, Headache, and WHO public health agenda 16:45 - 17:00 - 4. World Brain Day for Migraine and Other Headaches: A collective effort and responsibility</p>			
17:00	<p>Industry Symposia 17:00-18:30</p>			
18:30	<p>Welcome Reception 18:30 - 19:30</p>			

<p><b>Colour Key</b></p> <ul style="list-style-type: none"> <li><span style="display: inline-block; width: 15px; height: 10px; background-color: #d9ead3; border: 1px solid black; margin-right: 5px;"></span> Teaching Courses - Note 6 x TC's attendance FOC, duration 1.5hrs each, 6 speakers per TC</li> <li><span style="display: inline-block; width: 15px; height: 10px; background-color: #e0f0ff; border: 1px solid black; margin-right: 5px;"></span> Plenary Sessions -</li> <li><span style="display: inline-block; width: 15px; height: 10px; background-color: #e0f0ff; border: 1px solid black; margin-right: 5px;"></span> Parallel Sessions</li> <li><span style="display: inline-block; width: 15px; height: 10px; background-color: #e0f0ff; border: 1px solid black; margin-right: 5px;"></span> Industry Symposia</li> <li><span style="display: inline-block; width: 15px; height: 10px; background-color: #fff2cc; border: 1px solid black; margin-right: 5px;"></span> Exhibition</li> <li><span style="display: inline-block; width: 15px; height: 10px; background-color: #fff2cc; border: 1px solid black; margin-right: 5px;"></span> AGM</li> <li><span style="display: inline-block; width: 15px; height: 10px; background-color: #fff2cc; border: 1px solid black; margin-right: 5px;"></span> Oral Communications</li> <li><span style="display: inline-block; width: 15px; height: 10px; background-color: #fff2cc; border: 1px solid black; margin-right: 5px;"></span> Cephalalgia Award Lecture / Awards and Closing Ceremony</li> <li><span style="display: inline-block; width: 15px; height: 10px; background-color: #fff2cc; border: 1px solid black; margin-right: 5px;"></span> Coffee break / Lunch / Poster Walk</li> <li><span style="display: inline-block; width: 15px; height: 10px; background-color: #fff2cc; border: 1px solid black; margin-right: 5px;"></span> Social Activities</li> </ul>	<p><b>Sessions</b></p>
---	------------------------

FRIDAY 6 SEPTEMBER 2019

07:15	Industry Symposia 07:15 - 08:45			
09:00	Plenary Scientific Session 1 - CGRP and CGRP mAbs 09:00 - 10:00 Chair: M. Ashina (Denmark) 09:00-09:15 - Review lecture on CGRP role in migraine: evidence from clinical and preclinical studies (L. Edvinsson, Sweden) 09:15-09:30 - CGRP-mAbs overall efficacy, ability to completely eliminate migraine in some patients but make no difference for others, safety profile, and lack of CNS adverse events. (P.J. Goadsby, UK) 09:30-09:45 - Chronic episodic migraine, vs. chronic migraine: lessons learned from CGRP-mAbs (R. Burstein, USA) 09:45-10:00 - Discussion			
10:00	Plenary Scientific Session 2 - Why is it that almost all drugs and devices developed for the treatment of migraine succeed whereas almost all drugs and devices developed for pain fail? 10:00 - 11:00 Chair: P. Pozo-Rosich (Spain) 10:00-10:15 - Review clinical trials in pain and migraine in the past 20 years. (M. Ferrari, The Netherlands) 10:15-10:30 - Role of primary and secondary outcome measures in defining success and failure. (C. Tassorelli, Italy) 10:30-10:45 - Do we need more relevant clinical trial designs & endpoints for acute and prophylactic migraine treatment? (H.C. Diener, Germany) 10:45-11:00 - Discussion			
11:00	Break and Poster Walk I 11:00 - 12:00			
12:00	IHS Advisory Council 12:00-12:45			
12:45	Break and pick up lunch boxes 12:45 - 13:00			
13:00	Lunch Session 1 - Inflammation and migraine 13:00-14:00 13:00-13:15 - Clinical evidence for role of inflammation and anti-inflammatory drugs in migraine (J. Schoenen, Belgium) 13:15-13:20 - Discussion 13:20-13:35 - The inflammosome story (T. Dalkara, Turkey) 13:35-13:40 - Discussion 13:40-13:55 - Imaging inflammation in animal models of migraine. (A. Schain, USA) 13:55-14:00 - Discussion	Lunch Session 2 - The interplay between genetic and the environmental in paediatric headache 13:00 - 14:00 13:00-13:15 - Role of genetic in migraine onset in childhood (A. Hershey, USA) 13:15-13:30 - Role of environment in migraine onset in childhood (V. Guidetti, Italy) 13:30-13:45 - Does it matter? (A. Gelfand, USA) 13:45-14:00 - Discussion	Lunch Session 3 - Is there a role for endocannabinoids in the treatment of migraine or cluster headache? 13:00-14:00 Chair: E. Leroux (Canada) 13:00-13:20 - Cannabinoids: hopes or bluster and potential risks (B. McGeeney, USA) 13:20-13:40 - Endocannabinoids and marijuana: examining the basic science and the therapeutic benefit. (S. Silberstein, USA) 13:40-14:00 - Discussion	IHS fellowships 1 13:00-14:00 13:00-13:15 - Effects of CGRP antagonism on ischemic stroke outcomes in experimental animals (Inge Mulder, Netherlands) 13:15 - 13:30 - Exploring phasic changes of pain determination in migraine. (Kuan-Po Peng, Taiwan) 13:30 - 13:45 - Sulfotransferase inhibitors in the pathophysiology of migraine (Doga Vurali, Turkey) 13:45 - 14:00 - Deciphering the visual thalamic circuitry that modulates migraine events (Olivier Brock, United Kingdom)
14:00	One Topic Two Views 2 - Novel views on post-traumatic headache 14:00-15:00 Chair: A. Hershey (USA) 14:00-14:05 - Chairman Introduction Chairman questions: How can post-traumatic headache trigger chronic migraine if migraine is a genetic disorder? 14:05-14:25 - Post-traumatic headache is NOT a primary headache with head trauma as a trigger (T. Schwedt, USA) 14:25-14:45 - Psychogenic vs. neurogenic origin of post-traumatic headache. (G. Ifergan, Israel) 14:45-15:00 - Discussion	One Topic Two Views 3 - Behavioral animal models of migraine: are we wasting our time? 14:00-15:00 Chair: G. Dussor (USA) 14:00-14:05 - Chairman Introduction 14:05-14:25 - Behavioral animal model are not good enough to predict what will happen in the clinic (T. Ward, USA) 14:25-14:45 - Behavioral animal model are good enough to predict what will happen in the clinic (A. van den Maagdenberg, The Netherlands) 14:45-15:00 - Discussion	One Topic Two Views 1 - Are functional or structural brain changes cause or result of migraine and can they predict progression of disease? 14:00 - 15:00 14:00-14:05 - Chairman Introduction 14:05-14:20 - Structural brain changes are real and permanent (G. Terwindt, The Netherlands) 14:20-14:35 - Brain state vs. Brain trait (D. Borsook, USA) 14:35-14:50 - fMRI studies cannot predict progression of disease years before it occurs (A. Hougaard, Denmark) 14:50-15:00 - Discussion	Exhibition Open 09:00 - 17:30
15:00	Plenary Scientific Session 3 - IASP/IHS: Crosstalk between social interactions and pain behavior 15:00 - 16:00 Moderator: Arne May and Allen Finely 15:00-15:15 - Headache in social context (D. Buse, USA) 15:15-15:30 - Adolescents with chronic pain: Getting by with a little help from my friends (P. Forgeron, Canada) 15:30-15:45 - The importance of the social context in pain experience and expression (K. Craig, Canada) 15:45-16:00 - Discussion		Paediatrics session- Uncommon, but important headache disorders in Childhood 15:00-16:00 Migraine with motor aura- investigation and amnagement (I. Abu Arefeh, United Kingdom) Thunderclap Headache in adolescents (P. Prabhakar, London) Primary Stabbing Headache (M. Valeriani, Italy)	
16:00	Break 16:00 - 16:15			
16:15	One Topic Two Views 4 - Is aura a brain-damaging event? 16:15-17:15 16:15-16:20 - Chairman introduction 16:20-16:35 - Aura/CSD effect on vasculature and brain parenchyma (K.C. Brennan, USA) 16:35-16:50 - Aura and CSD are events that damage the brain and its vasculature - possible explanation for the increase risk of stroke (T. Kurth, Germany) 16:50-17:05 - Migraine aura: clinical implications for brain health (C. Ayata, USA) 17:05-17:15 - Discussion	One Topic Two Views 5 - Is cardiovascular risk a marketing gimmick or a real factor in treatment options? 16:15-17:15 Chair: S. Silberstein (USA) 16:15-16:20 - Chairman Introduction 16:20-16:40 - Cardiovascular risk in migraine and the implications for treatment options (A. Maassen van den Brink, The Netherlands) 16:40-17:00 - Cardiovascular risk does not commonly prevent the use of triptans (S. Sacco, Italy) 17:00-17:15 - Discussion	One Topic Two Views 6 - CGRP mAbs and CGRP receptor antagonists site of action 16:15 - 17:15 Chair: D. Hay (New Zealand) 16:15-16:20 - Chairman Introduction 16:20-16:40 - The central action of CGRP-mAb is the main reason for its efficacy (A. Charles, USA) 16:40-17:00 - The peripheral action of CGRP-mAb is the main reason for its efficacy (G. Dussor USA) 17:00-17:15 - Discussion	
17:15	Industry Symposia 17:15 - 18:45			
19:00				

Teaching Courses	Sessions
Plenary Sessions	Teaching Courses
Parallel Sessions - debate sessions proposal to include 2 x speakers 20 mins each, chairman 10 mins, Q&A 10 mins	Plenary Sessions
Industry Symposia	Parallel Sessions - debate sessions proposal to include 2 x speakers 20 mins each, chairman 10 mins, Q&A 10 mins
Exhibition	Industry Symposia
AGM	Exhibition
Oral Communications	AGM
Cephalalgia Award Lecture / Awards and Closing Ceremony	Oral Communications
Coffee break / Lunch / Poster Walk	Cephalalgia Award Lecture / Awards and Closing Ceremony
Social Activities	Coffee break / Lunch / Poster Walk
	Social Activities



SATURDAY 7 SEPTEMBER 2019				
07:15	Industry Symposia 07:15 - 08:45			
09:00	<p><b>One Topic Two Views 7 - What is the reason behind the higher prevalence of migraine in females than in males? Is it genetics or hormonal fluctuations that are the main factor?</b> Chair: B. Jenkins (Australia)</p> <p>09:00 - 10:00 09:00-09:05 - Chairman Introduction 09:05-09:25 - Differential expression of estrogen receptors in the trigeminovascular system male-female is the key behind higher prevalence of migraine in females (A. MacGregor, UK) 09:25-09:45 - Genetic differences between male and female is the main factor responsible for the higher numbers of migraine in female vs male (D. Nyholt, Australia) 09:45-10:00 - Discussion</p>	<p><b>One Topic Two Views 8 - Is migraine a CGRP disorder?</b> 09:00 - 10:00 09:00-09:05 - Chairman Introduction 09:05-09:25 - CGRP pathway is integral to migraine pathophysiology (A. Russo, USA) 09:25-09:45 - Migraine is not a CGRP disorder (M. Ashina, Denmark). 09:45-10:00 - Discussion</p>	<p><b>One Topic Two Views 9 - Is the migraine cortex inherently hyperresponsive: re-examining the defected habituation system</b> 09:00-10:00 09:00-09:05 - Chairman Introduction 09:05-09:25 - The migraine brain is inheritably hyper-responsive (G. Coppola, Italy) 09:25-09:45 - The migraine brain is not inheritably hyperexcitable (T. Sand, Norway) 09:45 - 10:00 - Discussion</p>	
10:00	Break and Poster Walk II 10:00-10:30			
10:30	<p><b>Oral communications 1</b> Chairs: C. Ayata (USA) &amp; M. Peres (Brazil) 6 speakers, 7+3 10:30- 11:30</p>	<p><b>Oral Communications 2</b> 6 speakers, 7+3 10:30-11:30</p>	<p><b>Oral Communications 3</b> Chairs: A. Ambrosini (Italy) &amp; T. Schwedt (USA) 6 speakers, 7+3 10:30-11:30</p>	
11:30	<p><b>Scientific session 4 - The CGRP-mAbs hype: The benefits, the ethics, the finance and the role of the treating physician.</b> 11:30 - 12:30 Moderators: Allan Purdy and Rami Burstein 11:30-11:35 - Moderators Introduction 11:35-11:55- The Emperor's New Gepants and the disappearance of therapeutic gain: Disturbing ethical and moral views (E. Loder, USA) 11:55-12:15 - What justifies the CGRP-mAbs hype? What should we tell or not tell patients? Is it our responsibility to fight for lower cost of these drugs? (D. Dodick, USA) 12:15-12:30 - Audience Discussion</p>			
12:30	Headache Science Excellence Tournament 12:30 - 13:30			
13:30	13:30-13:45			
13:45	<p><b>Lunch Session 4 - Triggers and prodromes</b> 13:45 - 14:45 Chair: D. Buse (USA) 13:45-14:00 - The problem with migraine triggers: is there an explanation for lack of consistency (R. Lipton, USA) 14:00-14:15 - The problem with migraine prodromes: is there an explanation for lack of consistency (M. Matharu, UK) 14:15-14:30 - Can physiological studies help answer these questions? (E. Tolner, The Netherlands) 14:30-14:45 - Discussion</p>	<p><b>Lunch Session 5 - Non-invasive neuromodulators role in the treatment of migraine and cluster headache: do they work and how?</b> 13:45 - 14:45 13:45-14:00 - Vagus nerve stimulation (S. Akerman, USA) 14:00-14:15 - Transcranial magnetic stimulation (A. Andreou, UK) 14:15 - 14:30 - Non-cranial nerve stimulators: (D. Yarnitsky, Israel) 14:30-14:45 - Discussion</p>	<p><b>Lunch Session 6 - Persistent idiopathic facial pain</b> 13:45 - 14:45 13:45 - 13:55 - Chronic and episodic versions of orofacial pain: New concepts (A. May, Germany) 13:55 -14:00 - Discussion 14:00-14:10 - Autoimmune facial pain : overlap between Neurology and Rheumatology (H. Ansari, USA) 14:10-14:15 - Discussion 14:15-14:25 - Differential diagnosis and treatment of temporomandibular disorders and trigeminal neuralgia, (M. Romero-Reyes, USA) 14:25-14:30 - Discussion 14:30-14:40 - Atypical facial pain (D. Mitsikostas, Greece) 14:40-14:45 - Discussion</p>	<p><b>LTB</b> GBD, IHME and the Global Campaign against Headache: influencing policy for best benefit 13:45 - 14:45 Chair: Z. Katsarava 13:45 - 14:00 - Using data to influence policy (IHME person)</p> <p><b>Informing policy in headache care:</b> 14:00 - 14:10 -The data from GBD, awareness, and the drivers of policy (L. Stovner, Norway) 14:10 - 14:20 - Adding data from children and adolescents (D. Uluduz, Turkey) 14:20 - 14:30 - Cost-effective intervention as the basis of policy (T.J. Steiner, UK) 14:30 - 14:45 - Discussion</p>
14:45	Break and Poster Walk III 14:45 - 15:45			
15:45	<p><b>Late Breaking Abstracts - Clinical</b> 6 speakers, 7+3 15:45-16:45</p>	<p><b>Late Breaking Abstracts - Basic</b> 6 speakers, 7+3 15:45-16:45</p>		
16:45	Cephalalgia Award Lecture 16:45-17:45			
17:45	Industry Symposia 17:45 - 18:45			
18:45				

Exhibition  
Open  
09:00 - 18:00

Colour Key	Sessions
Light Green	Teaching Courses
Light Blue	Plenary Sessions
Light Orange	Parallel Sessions
Light Purple	Industry Symposia
Light Yellow	Exhibition
Light Grey	AGM
Light Green	Oral Communications
Light Blue	Cephalalgia Award Lecture / Awards and Closing Ceremony
Light Orange	Coffee break / Lunch / Poster Walk
Light Grey	Social Activities



SUNDAY 8 SEPTEMBER 2019		
7:00	Industry Symposia 07:00 - 08:00	Exhibition Open 08:00 - 11:30
08:00	Late Breaking Industry Abstracts 12 speakers, 7+3 08:00 - 10:00	
10:00	Break	
10:15	Clinical and Basic Highlights 10:15 - 10:45	
10:45	Awards and Closing Ceremony 10:45-11:15	
11:15		

Colour Key	Sessions
[Green]	Teaching Courses
[Light Blue]	Plenary Sessions
[Orange]	Parallel Sessions
[Purple]	Industry Symposia
[Yellow]	Exhibition
[Light Green]	AGM
[Light Blue]	Oral Communications
[Grey]	Cephalalgia Award Lecture / Awards and Closing Ceremony
[Red]	Coffee break / Lunch / Poster Walk
[Light Grey]	Social Activities